Two Sigma Investments, LP Aerie Pharmaceuticals Inc Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $112,749 - $269,571	17,700 Added 59.34%	47,529 $719,000
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $124,433 - $230,264	-25,138 Reduced 45.73%	29,829 $224,000
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $206,474 - $358,768	36,609 Added 199.42%	54,967 $500,000
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $128,873 - $244,712	18,358 New	18,358 $129,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $2.05 Million - $3.01 Million	-181,018 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $788,486 - $986,648	-52,011 Reduced 22.32%	181,018 $2.9 Million
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $3.06 Million - $4.87 Million	233,029 New	233,029 $4.16 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.